SCHEMBL7266347

SCHEMBL7266347

COCCNc1nc(-c2ccc(Cl)cc2)nc2c(OC)c(OC)c(OC)cc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
PDE5A O76074 9/20 0.51
CYP1A2 P05177 6/20 0.45
CYP3A4 P08684 6/20 0.45
CYP2D6 P10635 4/20 0.45
ALDH1A1 P00352 4/20 0.45
CYP2C19 P33261 4/20 0.45
TSHR P16473 3/20 0.45
HSD17B10 Q99714 3/20 0.45
LMNA P02545 3/20 0.45
MAPT P10636 2/20 0.45
TP53 P04637 2/20 0.45
KDM4E B2RXH2 2/20 0.45
HPGD P15428 1/20 0.45
HBB P68871 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
ALOX15 P16050 3/20 0.44
USP2 O75604 2/20 0.44
CLK4 Q9HAZ1 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7268608 0.89 PDE5A (0.51) MEN1KMT2APDE5AMAPK1THRB
Hydrochloric Acid SCHEMBL7262070 0.88 PDE5A (0.50) MEN1KMT2APDE5AMAPK1THRB
SCHEMBL7267768 0.84 MEN1 (0.60) MEN1KMT2ACYP1A2CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL7266384 0.83 PDE5A (0.46) MEN1KMT2APDE5AALDH1A1HSD17B10
SCHEMBL7262631 0.80 GSK3A (0.52) MEN1KMT2ACYP1A2CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL7266393 0.79 MAPT (0.61) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL7261557 0.79 PDE5A (0.55) MEN1KMT2APDE5ACYP1A2CYP3A4
SCHEMBL5263213 0.78 DHPS (0.49) MEN1KMT2APDE5ALMNAMAPT
SCHEMBL7262644 0.78 MEN1 (0.71) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL5259174 0.76 PDE5A (0.44) MEN1KMT2APDE5ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6613772-B1 Drugs such as 2-(p-chlorophenyl-4-(4-hydroxybutyl)amino-6,7,8 -trimethoxyquinazoline used for activation of guanylate cyclase and modulation of cyclic guanosine monophosphate AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-09-02 US disclosed
EP-1040101-A1 SUBSTITUTED 2-ARYL-4-AMINO-CHINAZOLINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS Aventis Pharma Deutschland GmbH (DE) 2000-10-04 EP disclosed
WO-1999032460-A1 SUBSTITUTED 2-ARYL-4-AMINO-CHINAZOLINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 1999-07-01 WO disclosed